Lumbar spinal stenosis (LSS) accompanied by radicular sciatica frequently leads to early recommendations for surgical intervention. Nevertheless, longitudinal evidence demonstrates that conservative approaches can yield substantial improvement, with nearly half of affected individuals achieving meaningful symptom resolution without operative treatment within 4–10 years. This case report describes the author's personal clinical journey, a 50-year-old lifelong athlete at the time of the symptoms onset, who developed sudden, incapacitating left-sided sciatica (VAS 10/10) caused by severe multilevel lumbar spinal stenosis, predominantly involving L4-L5 and L5-S1. Despite neurosurgical advocacy intervention, operative treatment was declined. Across a five-year period (2020–2025), symptoms gradually and spontaneously resolved through adaptive self-directed conservative management. This culminated in full return to high-intensity athletic performance, including pain-free gym training, football, weekly tennis participation, skiing, and unrestricted recreational exercise. This narrative explores mechanisms of neural plasticity, highlights potential risks associated with premature surgical intervention, and emphasises the importance of persistence and shared decision-making in carefully selected patients. Additionally, it proposes that graded exposure to physiological stress through continued physical activity may activate intrinsic repair processes, challenging deterministic views of degenerative spinal disease progression.

The integration of artificial intelligence (AI) into healthcare promises transformative efficiencies, yet it also raises concerns about potential cost escalations. This paper examines a simulated patient-AI interaction involving a 56-year-old man, Edoardo, presenting with a persistent sore throat. Using this scenario as a foundation, we debate how AI-driven medical management might "spiral up" costs through over-reliance on diagnostics and protocols, contrasted with a human physician's common-sense approach that emphasizes clinical judgment to minimize unnecessary expenditures. Drawing on evidence from healthcare economics, clinical practices, and real-world implementations, I explore both sides to provide a balanced perspective on AI's role in cost management as of 2025.

Severe, topical-resistant chronic rhinosinusitis with nasal polyps (CRSwNP) in the United Kingdom is characterised by prolonged morbidity and prolonged access barriers to definitive secondary-care treatments. Current NHS ENT pathways routinely involve 52–78-week waits for specialist review and substantially longer intervals before revision surgery or biologic therapy can be initiated. Within primary care and severe-asthma services, where most biologic-eligible CRSwNP patients are now identified, there are few safe, rapidly deployable interim options. Repeated oral prednisolone is discouraged; intrapolyp steroid injection is impractical; and biologic therapy initiation is not supported by current guidelines. Nonetheless, longstanding clinical experience across multiple specialties supports the use of single-dose intramuscular (IM) depot steroids as an effective, adherence-proof, disease-modifying anti-inflammatory intervention. In eosinophilic polyposis, IM triamcinolone acetonide (40 mg) reliably induces near-complete regression within 1–3 weeks and delivers sustained benefit for 4–9 months, with smoother systemic exposure and lower cumulative glucocorticoid dose than standard oral tapering regimens. A comparative evaluation of pharmacokinetics, systemic exposure and safety demonstrates that a single 40 mg IM triamcinolone dose typically provides equal or superior symptom control, lower total steroid burden, and comparable safety to guideline-based oral prednisolone courses, while offering major advantages in convenience and adherence. Given the absence of accessible alternatives in UK primary care, IM triamcinolone represents a rational, evidence-aligned interim therapy for severe CRSwNP pending specialist management. A randomised controlled trial is warranted to establish definitive comparative efficacy, but current data and pragmatic clinical need strongly support its judicious use within primary care pathways.

Hypertrophic adipose tissue acts as a rogue, tumour-like endocrine organ, constitutively secreting pathogenic adipokines while suppressing protective ones, thereby driving insulin resistance, inflammation, hypertension, osteoarthritis, type 2 diabetes, hypogonadism, sarcopenia, and accelerated ageing. Tirzepatide, the first dual GLP-1/GIP agonist, reducing the adipose tissue, can yield profound benefits via mechanical unloading, pharmacodynamic amplification, functional rejuvenation, and direct endocrine silencing, leading to leptin sensitisation, and adiponectin rise, cytokine suppression, testosterone normalisation, reduced local cortisol/angiotensinogen. Consequences include biological age reversa, avoided joint replacements, polypharmacy reduction, and resolution of multimorbidity.

Traditional physician payment models based on volume or time fail to reward clinical outcomes, patient experience, and societal impact, particularly in primary care where general practitioners (GPs) provide holistic, preventive services undervalued relative to specialists like dermatologists. We develop a formal additive multi-attribute utility model that decomposes physician value into functional (Vf), social (Vs), and psychological (Vp) dimensions. Each sub-value is a weighted sum of observable features, with multiplicative terms to penalise poor execution. The composite metric Vm = αf Vf + αs Vs + αp Vp (where ∑α = 1) can be linked to payment via a budget parameter. Weights are elicited via analytic hierarchy process or structural equation modelling. A calibrated simulation illustrates incentive shifts, highlighting how GPs' superior holistic value could be better compensated compared to procedural specialists. Strengths include theoretical coherence and policy alignment; weaknesses centre on measurement error, endogeneity, and gaming risk. Phased implementation with robust data infrastructure is required. The model offers a scalable framework for value-based GP compensation, addressing income disparities and promoting equitable pay, but empirical validation remains essential.

Traditional physician payment models based on volume or time fail to reward clinical outcomes, patient experience, and societal impact. We develop a formal additive multi-attribute utility model that decomposes physician value into functional (V f), social (Vs), and psychological (Vp) dimensions. Each sub-value is a weighted sum of observable features, with multiplicative terms to penalise poor execution. The composite metric Vm = α f V f +αs Vs +αp Vp (where α = 1) can be linked to payment via a budget parameter. Weights are elicited via analytic hierarchy process or structural equation modelling. A calibrated simulation illustrates incentive shifts. Strengths include theoretical coherence and policy alignment; weaknesses centre on measurement error, endogeneity, and gaming risk. Phased implementation with robust data infrastructure is required. The model offers a scalable framework for value-based physician compensation, but empirical validation remains essential.

Background: Inflammatory disorders represent a major burden in general practice, spanning autoimmune diseases, metabolic-inflammatory conditions, and post-infectious syndromes. Their protean manifestations often lead to delayed diagnosis, fragmented care, and suboptimal outcomes. In the UK, these conditions account for a significant proportion of primary care consultations, with chronic low-grade inflammation implicated in up to 50% of multimorbidity cases.Aim: To explore the evolving understanding of inflammatory processes and their implications for diagnosis, management, and prevention in general practice.Design & Setting: Narrative review with a translational perspective, informed by clinical experience and current evidence from UK primary care settings. Method: Literature was synthesised from primary care, immunology, and neurophysiology domains, with emphasis on conditions presenting commonly in UK general practice. A targeted search of PubMed and Cochrane databases (2015–2025) was conducted using terms such as “inflammation”, “primary care”, “chronic disease”, and “general practice”. Additional insights were drawn from clinical observations in multimorbid patients and mechanistic studies in neurophysiology.Results: Advances in immunology and systems biology are reshaping the conceptualisation of inflammation, shifting from organ-specific syndromes to systemic dysregulation. This has direct implications for early detection (e.g., subtle inflammatory markers like high-sensitivity C-reactive protein [hsCRP] and cytokine profiles), multimorbidity management (e.g., cardiovascular and metabolic consequences of chronic inflammation), and therapeutic strategies (e.g., lifestyle interventions, biologics, integrated care models). Chronic inflammation serves as a unifying pathway across diseases, driven by lifestyle and environmental factors, with neuro-immune interactions offering novel therapeutic targets.Conclusion: General practice is uniquely positioned to recognise inflammatory patterns across the lifespan, integrate mechanistic insights into holistic care, and drive research that bridges the molecular and the everyday clinical. A renewed focus on inflammation in primary care could enhance both precision and person-centred medicine.Keywords: Inflammation, primary care, general practice, neuro-immune interactions, lifestyle interventions, multimorbidity

Despite decades of pharmacologic research, hypertension management remains constrained by rigid, stepwise dose adjustments that fail to account for inter-individual variability. Inspired by continuous glucose monitoring in diabetes, we present a novel simulator of adaptive ramipril dosing based on pharmacokinetic accumulation, patient-specific sensitivity, circadian patterns, and stochastic variability. Multi-daily drug administrations are simulated with incremental dose adjustments to achieve systolic and diastolic blood pressure (BP) targets. Simulations demonstrate that personalized, multi-daily dosing maintains BP within ideal ranges more effectively than standard fixed-dose regimens. This work provides a conceptual foundation for wearableguided, real-time antihypertensive therapy.

ABSTRACT Fit notes, issued by General Practitioners (GPs) in the UK, represent a medico-legal mechanism likened to a ”virtuous prescription,” yet they cost the economy £11 billion annually in lost productivity and welfare support. This paper reframes the fit note debate through a Platonic lens, emphasizing justice as harmony, equitable role assignment, and the pursuit of the common good. Critics highlight GPs’ lack of occupational health expertise and the risk of fostering dependency, while legal frameworks, rooted in the National Health Service Act 2006 and Equality Act 2010, uphold fit notes as a state duty. Drawing on clinical experience, legal analysis, and Platonic ethics, we propose reforms to align the system with justice, ensuring harmony between individual well-being and societal flourishing. KEYWORDS : justice, harmony, fit note, General Practitioners, equity, virtue, reform

Atrial fibrillation (AF) is a prevalent arrhythmia linked to increased risks of stroke, heart failure, and mortality. Conventional fixed-dose beta-blocker strategies for AF rate control, such as atenolol, fail to account for dynamic individual variability in heart rate (HR) and response. This paper introduces a conceptual framework for a wearable-based precision management system in AF, inspired by continuous glucose monitoring and precision hypertension models. The proposed system utilizes a wrist-worn HR monitor paired with a smartphone app to inform adaptive atenolol dosing in real-time. By employing machine learning for AF detection and adaptive algorithms to modulate dosing based on HR patterns, this approach aims to optimize rate control while minimizing side effects. A pilot study design

Chronic inflammatory dermatoses (CIDs), such as psoriasis, atopic dermatitis, and lichen planus, are characterized by persistent inflammation and immune dysregulation. Current treatments primarily target inflammatory pathways but often fail to achieve sustained remission. We propose that hyaluronic acid (HA), a key component of the extracellular matrix, plays a significant immunomodulatory role in CIDs. Specifically, the molecular weight of HA influences its interaction with immune receptors, modulating inflammatory responses. High-molecular-weight HA (HMW-HA) may exhibit anti-inflammatory properties by engaging CD44 receptors, leading to the suppression of pro-inflammatory cytokines. Conversely, low-molecular-weight HA (LMW-HA), resulting from tissue injury or degradation, may act as a damage-associated molecular pattern (DAMP), activating Toll-like receptors (TLR2 and TLR4) and promoting inflammation. This dualistic role of HA suggests that modulating its molecular weight distribution in the skin could offer a novel therapeutic approach for CIDs. Future research should focus on elucidating the mechanisms underlying HA's size-dependent effects on immune cells and exploring HA-based interventions to restore immune balance in CIDs.

Despite advances in medical technology, blood pressure (BP) management remains reliant on rigid, stepwise medication adjustments. In contrast, diabetes care has embraced dynamic, real-time insulin dosing through pumps and continuous glucose monitors (CGMs) (Nathan et al., 2005). Currently, hypertensive patients are prescribed medications like ramipril in fixed increments (e.g., 2.5 mg, 5 mg), despite individual differences in metabolism, receptor sensitivity, weight, and lifestyle factors (James et al., 2014). This one-size-fits-all approach often results in suboptimal treatment—either undercorrecting or overshooting the ideal BP target, increasing risks of cardiovascular events (Lawes et al., 2008).